NCT06003270

Biological Effects of Quercetin in COPD Phase II

Effects of Quercetin on the Oxidative Stress and Inflammatory Markers in COPD Phase II

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Temple University · Academic / Other
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study determines whether quercetin supplementation reduces the inflammation and oxidative stress markers in patients with chronic obstructive pulmonary disease. It is small study with 8 subjects receiving quercetin 1000 mg/day, 8 patients receiving 500 mg/day and 4 subjects receive placebo.

Detailed description

Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder and affects millions of people globally. Although the exact mechanisms of pathogenesis of this disease are not well-understood, the general consensus is that oxidative stress and inflammation induced by exposure to cigarette smoke or other environmental or occupational hazards are responsible for development of COPD. Therefore, therapies aimed at decreasing oxidative stress and inflammation constitutes an important component of treating COPD. The current pharmacological therapies may provide temporary symptom relief, reduce acute exacerbations and hospitalizations, but are associated with side effects. Therefore complementary method of treatment with potentially fewer side effects and relatively well-tolerated provide promising alternative. One such compound is quercetin, which is plant polyphenol and is present in variety of foods that we consume. Quercetin has potent antioxidant and anti-inflammatory properties and reduces oxidative stress and inflammation in a preclinical model of COPD. Quercetin exerts it antioxidant properties not only by neutralizing free radical species, but also by enhancing the expression of antioxidant enzymes. Similarly, quercetin inhibits various protein and lipid kinases by competing for adenosine triphosphate (ATP) binding sites thus reducing the inflammatory pathways.

Conditions

• Chronic Obstructive Pulmonary Disease
• Emphysema
• Chronic Bronchitis With Airway Obstruction

Interventions

Type	Name	Description
DRUG	Quercetin 1000 mg	Active comparator
DRUG	Quercetin 500 MG	Active comparator
DRUG	Placebo	Placebo comparator

Timeline

• Start date: 2023-11-01
• Primary completion: 2025-02-15
• Completion: 2025-07-31
• First posted: 2023-08-21
• Last updated: 2024-04-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study